ketorolac has been researched along with Pregnancy in 33 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.
Excerpt | Relevance | Reference |
---|---|---|
"To study the effect of ketorolac, a potent anti-inflammatory medication, on in vitro fertilization (IVF) pregnancy outcomes when used at the time of oocyte retrieval." | 7.79 | The effect of ketorolac on pregnancy rates when used immediately after oocyte retrieval. ( Hurst, BS; Kacemi-Bourhim, L; Marshburn, PB; Matthews, M; Mesen, TB; Norton, HJ; Usadi, RS, 2013) |
" Finally, the simultaneous increase in CL and Vss resulted in similar estimates for elimination half-life in both unpaired and paired analysis." | 6.84 | Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. ( Allegaert, K; De Hoon, J; Deprest, J; Kulo, A; Maleškić, S; Smits, A; Van Calsteren, K; Van de Velde, M; Verbesselt, R, 2017) |
"Postoperative pain was assessed using a visual analog scale (VAS)." | 6.77 | The effect of perioperative ketorolac on pain control in pregnancy termination. ( Fechner, A; James, D; Li, D; Roche, NE; Tilak, V, 2012) |
" Indomethacin was superior to celecoxib for pain score at rest at 8-12 h and celecoxib + parecoxib, diclofenac, and ketorolac for pain score on movement at 48 h." | 5.41 | Comparison of different nonsteroidal anti-inflammatory drugs for cesarean section: a systematic review and network meta-analysis. ( Blake, L; Carvalho, B; Carver, AL; Desai, N; Murdoch, I; O'Carroll, JE; Onwochei, DN; Sultan, P, 2023) |
"To study the effects of a paracervical block with combined ketorolac and lidocaine on perceived pain during first-trimester surgical abortion." | 5.14 | Paracervical block with combined ketorolac and lidocaine in first-trimester surgical abortion: a randomized controlled trial. ( Burke, A; Cansino, C; Edelman, A; Jamshidi, R, 2009) |
"To study the effect of ketorolac, a potent anti-inflammatory medication, on in vitro fertilization (IVF) pregnancy outcomes when used at the time of oocyte retrieval." | 3.79 | The effect of ketorolac on pregnancy rates when used immediately after oocyte retrieval. ( Hurst, BS; Kacemi-Bourhim, L; Marshburn, PB; Matthews, M; Mesen, TB; Norton, HJ; Usadi, RS, 2013) |
" Finally, the simultaneous increase in CL and Vss resulted in similar estimates for elimination half-life in both unpaired and paired analysis." | 2.84 | Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period. ( Allegaert, K; De Hoon, J; Deprest, J; Kulo, A; Maleškić, S; Smits, A; Van Calsteren, K; Van de Velde, M; Verbesselt, R, 2017) |
" These results suggest that administration of NSAIDs into surgical wounds may be an analgesic alternative to higher systemic dosing of NSAIDs." | 2.78 | Postoperative subcutaneous instillation of low-dose ketorolac but not hydromorphone reduces wound exudate concentrations of interleukin-6 and interleukin-10 and improves analgesia following cesarean delivery. ( Angst, MS; Carvalho, B; Lemmens, HJ; Ting, V, 2013) |
"Postoperative pain was assessed using a visual analog scale (VAS)." | 2.77 | The effect of perioperative ketorolac on pain control in pregnancy termination. ( Fechner, A; James, D; Li, D; Roche, NE; Tilak, V, 2012) |
"Morphine was basically used in PCA manner during the 3-day study course; and in Group K patients received an intravenous loading bolus of 30mg ketorolac post-operatively and then 90mg ketorolac combined with morphine in PCA fashion throughout the study course." | 2.75 | Comparison of the efficacy of parecoxib versus ketorolac combined with morphine on patient-controlled analgesia for post-cesarean delivery pain management. ( Cheu, NW; Chuang, FH; Liao, CH; Tan, TD; Wang, YR; Watts, MP; Wong, JO, 2010) |
"The ketorolac dose was modified, after six patients had been studied, based on new product information recommending a maximum of 120 mg ketorolac over 24 h." | 2.70 | The effect of intravenous ketorolac on opioid requirement and pain after cesarean delivery. ( Evans, SF; Paech, MJ; Pavy, TJ, 2001) |
"Ketorolac is a potent analgesic agent with antiplatelet properties which is known to cross the placenta." | 2.66 | Effect of maternal ketorolac administration of platelet function in the newborn. ( Greer, IA; Johnston, J; Tulloch, I; Walker, JJ, 1988) |
"Ketorolac is a nonsteroidal anti-inflammatory drug used as part of multimodal analgesia in women undergoing cesarean delivery." | 1.56 | Intra-operative ketorolac 15 mg versus 30 mg for analgesia following cesarean delivery: a retrospective study. ( Fuller, M; Habib, AS; Pedro, C; Yurashevich, M, 2020) |
" This suggests that postpartum is another specific status in young women that merits focused, compound-specific pharmacokinetic evaluation." | 1.38 | The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis. ( Allegaert, K; de Hoon, J; Devlieger, R; Kulo, A; Smits, A; van Calsteren, K; Verbesselt, R, 2012) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (3.03) | 18.7374 |
1990's | 7 (21.21) | 18.2507 |
2000's | 5 (15.15) | 29.6817 |
2010's | 14 (42.42) | 24.3611 |
2020's | 6 (18.18) | 2.80 |
Authors | Studies |
---|---|
Indermuhle, P | 1 |
Zelko, M | 1 |
Mori, C | 1 |
Chiu, SH | 1 |
Hostage, J | 1 |
Kolettis, D | 1 |
Sverdlov, D | 1 |
Ludgin, J | 1 |
Drzymalski, D | 1 |
Sweigart, B | 1 |
Mhatre, M | 1 |
House, M | 1 |
Murdoch, I | 1 |
Carver, AL | 1 |
Sultan, P | 1 |
O'Carroll, JE | 1 |
Blake, L | 1 |
Carvalho, B | 2 |
Onwochei, DN | 1 |
Desai, N | 1 |
Barney, EZ | 1 |
Pedro, CD | 2 |
Gamez, BH | 1 |
Fuller, ME | 1 |
Dominguez, JE | 1 |
Habib, AS | 3 |
Yurashevich, M | 2 |
Pedro, C | 1 |
Fuller, M | 2 |
Herbert, KA | 1 |
Bordlee, JW | 1 |
Beakley, BD | 1 |
Mody, R | 1 |
McConville, AP | 1 |
Weed, JT | 1 |
McClure, BP | 1 |
Foldes, PJ | 1 |
Ma, JG | 1 |
Kaye, AD | 1 |
Eskander, JP | 1 |
Wagner-Kovacec, J | 1 |
Povalej-Brzan, P | 1 |
Mekis, D | 1 |
Wilson, SH | 1 |
Wolf, BJ | 1 |
Robinson, SM | 1 |
Nelson, C | 1 |
Hebbar, L | 1 |
Shah, TH | 1 |
Rubenstein, AR | 1 |
Kosik, ES | 1 |
Heimbach, SW | 1 |
Madamangalam, AS | 1 |
Barnhart, ML | 1 |
Rosenbaum, K | 1 |
Hadley, EE | 1 |
Monsivais, L | 1 |
Pacheco, L | 1 |
Babazade, R | 1 |
Chiossi, G | 1 |
Ramirez, Y | 1 |
Ellis, V | 1 |
Simon, M | 1 |
Saade, GR | 1 |
Costantine, M | 1 |
Fay, EE | 1 |
Hitti, JE | 1 |
Delgado, CM | 1 |
Savitsky, LM | 1 |
Mills, EB | 1 |
Slater, JL | 1 |
Bollag, LA | 1 |
Mesen, TB | 1 |
Kacemi-Bourhim, L | 1 |
Marshburn, PB | 1 |
Usadi, RS | 1 |
Matthews, M | 1 |
Norton, HJ | 1 |
Hurst, BS | 1 |
Singh, SI | 1 |
Rehou, S | 1 |
Marmai, KL | 1 |
Jones, APM | 1 |
Kulo, A | 2 |
Smits, A | 2 |
Maleškić, S | 1 |
Van de Velde, M | 1 |
Van Calsteren, K | 2 |
De Hoon, J | 2 |
Verbesselt, R | 2 |
Deprest, J | 1 |
Allegaert, K | 2 |
El-Tahan, MR | 2 |
Warda, OM | 2 |
Yasseen, AM | 2 |
Matter, MK | 2 |
Cansino, C | 1 |
Edelman, A | 1 |
Burke, A | 1 |
Jamshidi, R | 1 |
Wong, JO | 1 |
Tan, TD | 1 |
Cheu, NW | 1 |
Wang, YR | 1 |
Liao, CH | 1 |
Chuang, FH | 1 |
Watts, MP | 1 |
Roche, NE | 1 |
Li, D | 1 |
James, D | 1 |
Fechner, A | 1 |
Tilak, V | 1 |
Devlieger, R | 1 |
Lemmens, HJ | 1 |
Ting, V | 1 |
Angst, MS | 1 |
Magnani, E | 1 |
Corosu, R | 1 |
Mancino, P | 1 |
Borgia, ML | 1 |
Attallah, MM | 1 |
Tzeng, JI | 1 |
Mok, MS | 1 |
Gin, T | 1 |
Kan, AF | 1 |
Lam, KK | 1 |
O'Meara, ME | 1 |
Laifer, SA | 2 |
Rauk, PN | 2 |
Ho, ML | 1 |
Chang, JK | 1 |
Chuang, LY | 1 |
Hsu, HK | 1 |
Wang, GJ | 1 |
Matambo, J | 1 |
Moodley, J | 1 |
Chigumadzi, P | 1 |
Pavy, TJ | 1 |
Paech, MJ | 1 |
Evans, SF | 1 |
Walker, JJ | 2 |
Johnston, J | 2 |
Fairlie, FM | 1 |
Lloyd, J | 1 |
Bullingham, R | 1 |
Greer, IA | 1 |
Tulloch, I | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery[NCT02829944] | Phase 4 | 84 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery[NCT02487303] | 148 participants (Actual) | Interventional | 2015-03-17 | Completed | |||
Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial[NCT02922985] | Phase 4 | 120 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
The Effect of Enhanced Recovery After Surgery (ERAS) for Cesarean Section on Neonatal Blood Glucose - A Randomized Equivalency Trial[NCT05081804] | 216 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | |||
Improving Pain Perceptions After Initiating a Delivery Application[NCT04822493] | 83 participants (Actual) | Interventional | 2021-01-01 | Completed | |||
A Randomized Blinded Placebo Controlled Trial Assessing Ketorolac (Toradol) at Oocyte Retrieval[NCT06026553] | Phase 1 | 400 participants (Anticipated) | Interventional | 2022-08-10 | Recruiting | ||
Effect of Low-dose Epidural Morphine Combined With Single-injection Femoral Nerve Block on Postoperative Analgesia in Patients After Total Knee Arthroplasty[NCT03203967] | 110 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
Paracervical Block for Pain Control During Osmotic Dilator Placement: a Randomized Controlled Trial[NCT02354092] | 14 participants (Actual) | Interventional | 2015-04-02 | Terminated | |||
Paracervical Block With Ketorolac and Lidocaine in First Trimester Surgical Abortions[NCT00617097] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
Pain Control for Intrauterine Device Placement: A Randomized, Double Blind Control Trial of Ketorolac Prior to Intrauterine Device Placement.[NCT01664559] | 67 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
Pain Control for Intrauterine Device Placement: A Randomized Controlled Trial of Paracervical Block[NCT02219308] | 67 participants (Actual) | Interventional | 2014-10-31 | Completed | |||
Prospective Evaluation of the Effects of IV Ketorolac on Platelet Function Post-Cesarean Delivery[NCT03805607] | Phase 4 | 40 participants (Actual) | Interventional | 2021-01-18 | Active, not recruiting | ||
Effect of Single Intravenous Ketamine Dose on Postoperative Pain Following Cesarean Section Under Spinal Anesthesia: A Randomized Control Clinical Trial.[NCT03018301] | Phase 2 | 80 participants (Anticipated) | Interventional | 2017-01-31 | Recruiting | ||
A Prospective, Randomized, Control Trial of Ketorolac Versus Placebo on Opioid Analgesic Use, Estimated Blood Loss and Complications Following Cesarean Delivery With Epidural Morphine[NCT02509312] | Phase 4 | 70 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 2 hours
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 14 |
Ropivacaine | 12 |
Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 24 hours
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 9 |
Ropivacaine | 7 |
Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 48 hours
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 4 |
Ropivacaine | 1 |
Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 2 hours
Intervention | score on a scale (Median) |
---|---|
Placebo | 4 |
Ropivacaine | 5.5 |
Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 24 hours
Intervention | units on a scale (Median) |
---|---|
Placebo | 3.5 |
Ropivacaine | 4 |
Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 48 hours
Intervention | score on a scale (Mean) |
---|---|
Placebo | 0 |
Ropivacaine | 0 |
Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 2 hours
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 7 |
Ropivacaine | 8 |
Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 24 hours
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 4 |
Ropivacaine | 4 |
Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 48 hours
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 1 |
Ropivacaine | 0 |
Phone interview asking patient about presence of pain at incision site (NCT02829944)
Timeframe: 6 months
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 0 |
Ropivacaine | 0 |
Phone interview asking patient about presence of pain at incision site (NCT02829944)
Timeframe: 8 weeks
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 3 |
Ropivacaine | 3 |
measured in mg oxycodone equivalents (NCT02829944)
Timeframe: 2 hours
Intervention | mg Oxycodone Equivalent (Median) |
---|---|
Placebo | 0 |
Ropivacaine | 0 |
measured in mg oxycodone equivalents (NCT02829944)
Timeframe: 24 hours
Intervention | mg Oxycodone Equivalent (Median) |
---|---|
Placebo | 5 |
Ropivacaine | 5 |
measured in mg oxycodone equivalents (NCT02829944)
Timeframe: 48 hours
Intervention | mg Oxycodone Equivalent (Mean) |
---|---|
Placebo | 20 |
Ropivacaine | 10 |
Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 48 hours after surgery
Intervention | score on a scale (Median) |
---|---|
Placebo | 5.5 |
Ropivacaine | 5 |
Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 24 hours after surgery
Intervention | score on a scale (Median) |
---|---|
Placebo | 5 |
Ropivacaine | 5 |
Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 2 hours
Intervention | score on a scale (Median) |
---|---|
Placebo | 2 |
Ropivacaine | 0 |
Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 24 hours
Intervention | score on a scale (Mean) |
---|---|
Placebo | 2 |
Ropivacaine | 2 |
Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 48 hours
Intervention | score on a scale (Median) |
---|---|
Placebo | 2 |
Ropivacaine | 2 |
Score reported on a scale of 0-10, with 0 being not at all satisfied and 10 being completely satisfied (NCT02829944)
Timeframe: 48 hours
Intervention | score on a scale (Median) |
---|---|
Placebo | 9.5 |
Ropivacaine | 8 |
Patients contacted over the phone completed screening with the EPDS, on a scale of 0-30. A score of over 13 indicate risk for postpartum depression (NCT02829944)
Timeframe: 6 months
Intervention | Participants (Count of Participants) |
---|---|
Placebo | 3 |
Ropivacaine | 1 |
Patients contacted over the phone completed screening with the EPDS, on a scale of 0-30. A score of over 13 indicate risk for postpartum depression (NCT02829944)
Timeframe: 8 weeks
Intervention | units on a scale (Median) |
---|---|
Placebo | 1 |
Ropivacaine | 0.5 |
(NCT02829944)
Timeframe: 48 hours
Intervention | Minutes (Mean) |
---|---|
Placebo | 660 |
Ropivacaine | 954 |
Cumulative opiate consumption (IV morphine equivalents) (NCT02487303)
Timeframe: 24 hours
Intervention | mg (Mean) |
---|---|
Acetaminophen Intravenous | 2.9 |
Acetaminophen Oral | 3.8 |
No Acetaminophen | 5.7 |
Time patient meets discharge criteria will be recorded (NCT02487303)
Timeframe: 24 hours postoperative
Intervention | hours (Mean) |
---|---|
Acetaminophen Intravenous | 48.4 |
Acetaminophen Oral | 48.6 |
No Acetaminophen | 50.5 |
Time to first opiate pain medicine requested by patient (NCT02487303)
Timeframe: 48 hours
Intervention | hours (Mean) |
---|---|
Acetaminophen Intravenous | 25.3 |
Acetaminophen Oral | 24.0 |
No Acetaminophen | 21.3 |
"Visual Analog Scale (VAS) pain assessment with ambulation. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain and worst pain. For pain intensity, the scale is most commonly anchored by no pain (score of 0) and pain as bad as it could be or worst imaginable pain (score of 100 [100-mm scale]) ." (NCT02487303)
Timeframe: 24 hours
Intervention | units on a scale (Mean) |
---|---|
Acetaminophen Intravenous | 37.8 |
Acetaminophen Oral | 44.3 |
No Acetaminophen | 50.8 |
This is the Apgar score of the newborn collected at 5 minutes. Range is from 0-10, with the higher scores meaning a better outcome. (NCT02922985)
Timeframe: 5 minutes after birth
Intervention | score on a scale (Median) |
---|---|
Placebo Control Group | 9 |
Multimodal Pain Regimen Group | 9 |
Time to discharge from hospital, measured in hours (NCT02922985)
Timeframe: From time of hospital admission to time of discharge home up to 168 hours.
Intervention | hours (Median) |
---|---|
Placebo Control Group | 50.2 |
Multimodal Pain Regimen Group | 50 |
neonate receipt of oxygen by nasal cannula or mechanical ventilation (NCT02922985)
Timeframe: after birth and before hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Placebo Control Group | 0 |
Multimodal Pain Regimen Group | 4 |
Rate of admission to the neonatal intensive care unit (NCT02922985)
Timeframe: after birth and before hospital discharge
Intervention | Participants (Count of Participants) |
---|---|
Placebo Control Group | 2 |
Multimodal Pain Regimen Group | 6 |
Number of opioid pain tablets remaining on post-operative day #7 from hospital discharge as reported by patients (NCT02922985)
Timeframe: 7 days post delivery
Intervention | Tablets (Median) |
---|---|
Placebo Control Group | 18 |
Multimodal Pain Regimen Group | 19 |
Pain Score at 24 Hours Post Operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 24 hours post-operatively
Intervention | score on a scale (Median) |
---|---|
Placebo Control Group | 5 |
Multimodal Pain Regimen Group | 6 |
Pain Score at 48 Hours Post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 48 hours post-operatively
Intervention | score on a scale (Median) |
---|---|
Placebo Control Group | 4 |
Multimodal Pain Regimen Group | 3 |
Pain score at 6-12 hours post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 6-12 hours post-operatively
Intervention | score on a scale (Median) |
---|---|
Placebo Control Group | 6 |
Multimodal Pain Regimen Group | 6 |
Time, in hours, to first administration of opioid pain medication post operatively (NCT02922985)
Timeframe: 48 hours post cesarean delivery
Intervention | hours (Median) |
---|---|
Placebo Control Group | 6.05 |
Multimodal Pain Regimen Group | 6.35 |
Every opioid intake by the patient in the first 48 hours after CD will be recorded and quantified in morphine milligram equivalents (NCT02922985)
Timeframe: 48 hours post cesarean delivery
Intervention | morphine milligram equivalents (Median) |
---|---|
Placebo Control Group | 42 |
Multimodal Pain Regimen Group | 49.5 |
"Measure of distance (mm) from the left (no pain) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after osmotic dilator placement. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain." (NCT02354092)
Timeframe: Within 5 minutes of PCB or sham procedure
Intervention | units on a scale (Mean) |
---|---|
Sham Group | 46 |
Paracervical Block Group | 32 |
"Measure of distance (mm) from the left (no pain) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded 15 minutes after osmotic dilator placement. mm=No Pain and 100 mm= worst possible pain. A higher mean score indicates a higher level of pain experienced at this time point." (NCT02354092)
Timeframe: 15 minutes after dilator placement
Intervention | units on a scale (Mean) |
---|---|
Sham Group | 42 |
Paracervical Block Group | 35 |
"Measure of distance (mm) from the left (no pain) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after last injection for paracervical block OR script for sham injection. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain." (NCT02354092)
Timeframe: Within 5 minutes after baseline
Intervention | units on a scale (Mean) |
---|---|
Sham Group | 19 |
Paracervical Block Group | 39 |
"Measure of distance (mm) from the left (no pain) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) of pain recorded at baseline prior to the paracervical block or sham block procedure. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain." (NCT02354092)
Timeframe: Baseline, just prior to PCB or sham procedure
Intervention | units on a scale (Mean) |
---|---|
Sham Group | 4 |
Paracervical Block Group | 19 |
fever, chills, vomiting, heavy bleeding/clots (collected without regard to the specific event) (NCT00617097)
Timeframe: end of study (upon discharge from facility after procedure)
Intervention | participants (Number) |
---|---|
Paracervical Block With Lidocaine | 3 |
Paracervical Block With Ketorolac and Lidocaine | 0 |
100-mm Visual Analogue Scale -- minimum: 0 mm (lower satisfaction), maximum: 100 mm (greater satisfaction) (NCT00617097)
Timeframe: end of study (prior to clinic discharge)
Intervention | mm (Mean) |
---|---|
Paracervical Block With Lidocaine | 62.9 |
Paracervical Block With Ketorolac and Lidocaine | 63.6 |
(NCT00617097)
Timeframe: end of study
Intervention | participants (Number) | |
---|---|---|
minor | serious | |
Paracervical Block With Ketorolac and Lidocaine | 1 | 2 |
Paracervical Block With Lidocaine | 1 | 0 |
"100-mm Visual Analogue Scale (VAS) during specific time intervals of D&C procedure: minimum: 0 mm (less pain); maximum: 100 mm (more pain)~Time intervals include: basline expected level of pain during procedure, after speculum insertion, at paracervical block injection, after dilation, end of procedure, and 30 minutes after procedure." (NCT00617097)
Timeframe: Baseline, Speculum Insertion, at Paracervical block injection, After dilation, End of procedure, 30 minutes after procedure
Intervention | mm (Mean) | |||||
---|---|---|---|---|---|---|
expected level of pain during procedure | after speculum insertion | during paracervical block administration | after cervical dilation | immediately after procedure | 30 min after procedure | |
Paracervical Block With Ketorolac and Lidocaine | 51.7 | 32.7 | 46.0 | 59.8 | 64.3 | 17.6 |
Paracervical Block With Lidocaine | 52.2 | 33.6 | 50.8 | 74.8 | 61.5 | 21.8 |
The patient marked their pain on a 0 to 10cm visual analogue scale, where 0 cm is no pain and 10 cm is the worst pain ever. (NCT01664559)
Timeframe: Pain with IUD placement, measured immediately after placement
Intervention | units on a scale (Median) |
---|---|
Placebo With 1cc Normal Saline IM | 5.2 |
Toradol, 30mg in 1cc IM | 3.6 |
"The patient marked their pain on a 0 to 10cm visual analogue scale, where 0 cm is no pain and 10 cm is the worst pain ever.~Prior to injection of study drug, anticipated pain~Pain from study drug injection, measured immediately after injection~Pain from speculum insertion, measured immediately after insertion~Pain with tenaculum placement, measured immediately after placement~Pain with uterine sounding, measured immediately after removal of the sound~Pain at 5 minutes after placement of the intrauterine device~Pain at 15 minutes after placement of the intrauterine device" (NCT01664559)
Timeframe: immediately after each step (see description)
Intervention | cm (Median) | |||||||
---|---|---|---|---|---|---|---|---|
1) Anticipated pain | 2) Pain with injection | 3) Speculum insertion | 4) Tenaculum placement | 5) Uterine sounding | 6) Pain with IUD placement | 7) 5 min after placement | 8) 15 min after placement | |
Placebo With 1cc Normal Saline IM | 2.8 | 1.8 | 2.3 | 6.3 | 8.4 | 8.1 | 3.7 | 4.8 |
Toradol, 30mg in 1cc IM | 3.6 | 1.2 | 1.5 | 4.3 | 6.0 | 5.4 | 2.7 | 1.8 |
"The patient marked their pain on a 0 to 10cm visual analogue scale, where 0 cm is no pain and 10 cm is the worst pain ever.~Prior to injection of study drug, anticipated pain~Pain from study drug injection, measured immediately after injection~Pain from speculum insertion, measured immediately after insertion~Pain with tenaculum placement, measured immediately after placement~Pain with uterine sounding, measured immediately after removal of the sound~Pain at 5 minutes after placement of the intrauterine device~Pain at 15 minutes after placement of the intrauterine device" (NCT01664559)
Timeframe: immediately after each step (see description)
Intervention | cm (Median) | ||||||
---|---|---|---|---|---|---|---|
Anticipated pain | Pain with injection | Speculum insertion | Tenaculum placement | Uterine sounding | 5 min after procedure | 15 min after procedure | |
Placebo With 1cc Normal Saline IM | 4.4 | 1.0 | 2.6 | 3.9 | 5.0 | 2.2 | 1.6 |
Toradol, 30mg in 1cc IM | 3.5 | 0.6 | 1.5 | 2.5 | 4.3 | 0.3 | 0.1 |
"Questions assessed in multiple choice format:~Side effects~injection site pain~overall satisfaction with IUD insertion experience~would they still recommend IUD placement to a friend?~significant pain for which they desired acetaminophen prior to leaving the office?" (NCT01664559)
Timeframe: assessed at 15 minutes after IUD insertion
Intervention | participants (Number) | ||||
---|---|---|---|---|---|
Reported side effects | Injection site pain - just as bad/worse than IUD | Satisfied or very satisfied with overall IUD proc | Recommend IUD to a friend | Desires additional pain medication | |
Placebo With 1cc Normal Saline IM | 12 | 8 | 30 | 28 | 16 |
Toradol, 30mg in 1cc IM | 8 | 6 | 31 | 30 | 6 |
"The provider will be asked to fill out a multiple choice format questionnaire:~what level training are you?~which IUD was inserted?~what was the purpose of IUD placement?~what was the position of the uterus?~did the IUD placement process require cervical dilation?~were you able to complete the IUD insertion?~was there bleeding from the cervix that required more than 5 min to control?~were there any major complications with the IUD insertion?~did the patient take tylenol prior to leaving the office?" (NCT01664559)
Timeframe: Immediately after IUD placement, on average within 1 hour
Intervention | participants (Number) | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Level of training - PGY1 | Level of training - PGY2 | Level of training - PGY3 | Level of training - PGY4 | Level of training - Attending | IUD type - levonogestrel | IUD type - copper | Purpose of IUD - contraception | Purpose of IUD - AUB | Position of uterus - anteverted | Position of uterus - retroverted | Position of uterus - midpositioned | Cervical dilation needed | Able to complete the IUD placement | Significant bleeding | Major complications | Took acetaminophen prior to leaving the office | |
Placebo With 1cc Normal Saline IM | 2 | 2 | 3 | 5 | 1 | 22 | 12 | 33 | 1 | 19 | 6 | 9 | 2 | 34 | 0 | 0 | 17 |
Toradol, 30mg in 1cc IM | 5 | 13 | 6 | 6 | 3 | 28 | 2 | 32 | 1 | 20 | 5 | 8 | 2 | 33 | 2 | 0 | 7 |
Distance (mm) from the left of the 100-mm visual analog scale (reflecting magnitude of pain) recorded at time of IUD Placement. Scale range is from 0mm (no pain) to 100mm (worst pain possible). A lower score (less pain) is considered a better outcome. (NCT02219308)
Timeframe: Moment of IUD insertion
Intervention | mm (Median) |
---|---|
No Paracervical Block (Sham PCB) | 54 |
Paracervical Block (PCB) | 33 |
Distance (mm) from the left of the 100-mm visual analog scale of pain at various time points. Scale range is 0mm (no pain) to 100mm (worst pain possible). Lower scores are considered better outcomes. (NCT02219308)
Timeframe: Anticipation of procedure through 5 minutes after IUD placement
Intervention | mm (Median) | ||||||||
---|---|---|---|---|---|---|---|---|---|
Anticipated Pain | Baseline Pain | Speculum Insertion | Capped Needle or PCB | Tenaculum placement | Uterine Sounding | IUD placement | 5 mins after IUD placement | Overall pain | |
No Paracervical Block (Sham PCB) | 51 | 0 | 6 | 8 | 10 | 47 | 54 | 27 | 51 |
Paracervical Block (PCB) | 58 | 0 | 10 | 30 | 15 | 30 | 33 | 12 | 30 |
Total doses of medications to treat pruritus (opioid side-effect) including ondansetron and promethazine. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
Intervention | doses (Median) |
---|---|
Ketorolac | 0 |
Placebo | 0 |
Corrected change in Hct on POD1. Performed by subtracting POD1 Hct from POD0 Hct. Correction for transfusion by further subtracting 3 per unit of pRBC transfused to account for the typical change seen per unit transfused. (NCT02509312)
Timeframe: POD1
Intervention | mg/dl (Mean) |
---|---|
Ketorolac | -5.1 |
Placebo | -3.5 |
Estimation of blood loss during surgery (NCT02509312)
Timeframe: Immediately post-op
Intervention | ml (Median) |
---|---|
Ketorolac | 900 |
Placebo | 800 |
Rate of Post-Partum Hemorrhage between groups during the first 24 hours pst-partum. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
Intervention | Participants (Count of Participants) |
---|---|
Ketorolac | 7 |
Placebo | 4 |
Total doses of medications to treat pruritus (opioid side-effect) including diphenhydramine, nalbuphine and naloxone. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
Intervention | doses (Median) |
---|---|
Ketorolac | 0 |
Placebo | 0 |
Total hydromorphone doses in mg in the first 24 hours post-partum. (NCT02509312)
Timeframe: 0 - 24 hours post-partum.
Intervention | mg (Median) |
---|---|
Ketorolac | 0 |
Placebo | 0.2 |
Total number of Units of Packed Reb Blood Cell Transfused in intra-op until 24 hours post-partum. (NCT02509312)
Timeframe: Intra-op until 24 hours post-partum.
Intervention | units of pRBCs (Median) |
---|---|
Ketorolac | 0 |
Placebo | 0 |
Total number of uterotonic doses including methylergonovine, carboprost and misoprostol. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
Intervention | doses (Median) |
---|---|
Ketorolac | 0 |
Placebo | 0 |
Pain score post-Cesarean Delivery using 11-point numerical rating scale (NRS): 0-10 where 0 is no pain and 10 is the worst pain imaginable (NCT02509312)
Timeframe: Up to 24 hours post-cesarean delivery
Intervention | units on NRS (Median) | |||||
---|---|---|---|---|---|---|
Baseline | 15 mins | 1 hour | 6 hours | 12 hours | 24 hours | |
Ketorolac | 0 | 0 | 0 | 1 | 2 | 4.5 |
Placebo | 0 | 0 | 0 | 3 | 3.5 | 5.5 |
Percentile change in diastolic Blood Pressure at 6,12, and 24 hours for each patient's baseline defined by immediate post-op PACU vitals. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
Intervention | Percent change (Mean) | ||
---|---|---|---|
6 hours | 12 hours | 24 hours | |
Ketorolac | 12.30 | 8.8 | 12.0 |
Placebo | 7.6 | 8.8 | 11.1 |
Percentile change in Systolic Blood Pressure at 6,12, and 24 hours for each patient's baseline defined by immediate post-op PACU vitals. (NCT02509312)
Timeframe: 0 - 24 hours post-partum
Intervention | Percent change (Mean) | ||
---|---|---|---|
6 hours | 12 hours | 24 hours | |
Ketorolac | -2.0 | -9.10 | -5.9 |
Placebo | -0.6 | -2.85 | -3.5 |
1 review available for ketorolac and Pregnancy
Article | Year |
---|---|
Comparison of different nonsteroidal anti-inflammatory drugs for cesarean section: a systematic review and network meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cesarean Section; Diclofenac; Female; Humans; In | 2023 |
18 trials available for ketorolac and Pregnancy
Article | Year |
---|---|
Increased Scheduled Intravenous Ketorolac After Cesarean Delivery and Its Effect on Opioid Use: A Randomized Controlled Trial.
Topics: Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Humans; Ke | 2023 |
Ropivacaine and Ketorolac Wound Infusion for Post-Cesarean Delivery Analgesia: A Randomized Controlled Trial.
Topics: Adult; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesics, Opioid; Anesthetics, Local | 2020 |
Efficacy of continuous in-wound infusion of levobupivacaine and ketorolac for post-caesarean section analgesia: a prospective, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Anesthetics, Local; Cesarean Section; Double-Blind Method; Female; Humans; Infusions, Intrale | 2018 |
Intravenous vs Oral Acetaminophen for Analgesia After Cesarean Delivery: A Randomized Trial.
Topics: Acetaminophen; Administration, Intravenous; Administration, Oral; Adult; Analgesics, Non-Narcotic; A | 2019 |
Multimodal Pain Management for Cesarean Delivery: A Double-Blinded, Placebo-Controlled, Randomized Clinical Trial.
Topics: Acetaminophen; Adult; Analgesia, Obstetrical; Analgesics, Non-Narcotic; Analgesics, Opioid; Anesthet | 2019 |
The efficacy of 2 doses of epidural morphine for postcesarean delivery analgesia: a randomized noninferiority trial.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroid | 2013 |
The efficacy of 2 doses of epidural morphine for postcesarean delivery analgesia: a randomized noninferiority trial.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroid | 2013 |
The efficacy of 2 doses of epidural morphine for postcesarean delivery analgesia: a randomized noninferiority trial.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroid | 2013 |
The efficacy of 2 doses of epidural morphine for postcesarean delivery analgesia: a randomized noninferiority trial.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroid | 2013 |
Enantiomer-specific ketorolac pharmacokinetics in young women, including pregnancy and postpartum period.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Case-Contr | 2017 |
Paracervical block with combined ketorolac and lidocaine in first-trimester surgical abortion: a randomized controlled trial.
Topics: Abortion, Induced; Adult; Anesthesia, Obstetrical; Anesthetics, Local; Anti-Inflammatory Agents, Non | 2009 |
Paracervical block with combined ketorolac and lidocaine in first-trimester surgical abortion: a randomized controlled trial.
Topics: Abortion, Induced; Adult; Anesthesia, Obstetrical; Anesthetics, Local; Anti-Inflammatory Agents, Non | 2009 |
Paracervical block with combined ketorolac and lidocaine in first-trimester surgical abortion: a randomized controlled trial.
Topics: Abortion, Induced; Adult; Anesthesia, Obstetrical; Anesthetics, Local; Anti-Inflammatory Agents, Non | 2009 |
Paracervical block with combined ketorolac and lidocaine in first-trimester surgical abortion: a randomized controlled trial.
Topics: Abortion, Induced; Adult; Anesthesia, Obstetrical; Anesthetics, Local; Anti-Inflammatory Agents, Non | 2009 |
Comparison of the efficacy of parecoxib versus ketorolac combined with morphine on patient-controlled analgesia for post-cesarean delivery pain management.
Topics: Adult; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesics, Opioid; Cesarean Section; | 2010 |
The effect of perioperative ketorolac on pain control in pregnancy termination.
Topics: Abortion, Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Huma | 2012 |
The effect of perioperative ketorolac on pain control in pregnancy termination.
Topics: Abortion, Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Huma | 2012 |
The effect of perioperative ketorolac on pain control in pregnancy termination.
Topics: Abortion, Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Huma | 2012 |
The effect of perioperative ketorolac on pain control in pregnancy termination.
Topics: Abortion, Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Huma | 2012 |
Postoperative subcutaneous instillation of low-dose ketorolac but not hydromorphone reduces wound exudate concentrations of interleukin-6 and interleukin-10 and improves analgesia following cesarean delivery.
Topics: Adult; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Bupivacaine; | 2013 |
Postoperative analgesia after cesarean section by continued administration of levobupivacaine with the On-Q Painbuster system over the fascia vs ketorolac + morphine i.v.
Topics: Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Bupivacaine; Cesare | 2006 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
A randomized study of the effects of preoperative ketorolac on general anaesthesia for caesarean section.
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Apgar | 2007 |
Combination of intramuscular Ketorolac and low dose epidural morphine for the relief of post-caesarean pain.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesics, Non-Narcotic; Anti-Inflammatory Agen | 1994 |
Analgesia after caesarean section with intramuscular ketorolac or pethidine.
Topics: Adult; Analgesics; Anesthesia, General; Cesarean Section; Double-Blind Method; Elective Surgical Pro | 1993 |
The effect of intravenous ketorolac on opioid requirement and pain after cesarean delivery.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesics, Opioi | 2001 |
The effect of intravenous ketorolac on opioid requirement and pain after cesarean delivery.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesics, Opioi | 2001 |
The effect of intravenous ketorolac on opioid requirement and pain after cesarean delivery.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesics, Opioi | 2001 |
The effect of intravenous ketorolac on opioid requirement and pain after cesarean delivery.
Topics: Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesics, Opioi | 2001 |
A comparative study of intramuscular ketorolac and pethidine in labour pain.
Topics: Adolescent; Adult; Analgesia, Obstetrical; Apgar Score; Double-Blind Method; Female; Humans; Hypnoti | 1992 |
Effect of maternal ketorolac administration of platelet function in the newborn.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Fetus; Humans; Infant, Newborn; Ketorolac; Maternal | 1988 |
14 other studies available for ketorolac and Pregnancy
Article | Year |
---|---|
Use of Scheduled Nonopioid Analgesia to Decrease Inpatient Opioid Consumption After Scheduled Cesarean Birth.
Topics: Acetaminophen; Analgesia; Analgesics, Non-Narcotic; Analgesics, Opioid; Female; Humans; Ibuprofen; I | 2022 |
Intra-operative ketorolac 15 mg versus 30 mg for analgesia following cesarean delivery: a retrospective study.
Topics: Adult; Analgesia, Obstetrical; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Dose-Respo | 2020 |
Impact of a multimodal analgesic protocol modification on opioid consumption after cesarean delivery: a retrospective cohort study.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 2022 |
A case of paradoxical presentation of a postural postdural puncture headache after combined spinal-epidural anesthesia.
Topics: Acetaminophen; Adult; Analgesics, Opioid; Anesthesia, Epidural; Anesthesia, Obstetrical; Anesthesia, | 2017 |
Parturient on Magnesium Infusion and Its Effectiveness as an Adjuvant Analgesic after Cesarean Delivery: A Retrospective Analysis.
Topics: Adult; Analgesia, Obstetrical; Analgesics; Anesthesia, Spinal; Cesarean Section; Female; Humans; Inf | 2018 |
Anaphylactoid Syndrome of Pregnancy.
Topics: Adult; Antipruritics; Atropine; Cyclooxygenase Inhibitors; Female; Humans; Hypotension; IgA Vasculit | 2019 |
An enhanced recovery after surgery pathway for cesarean delivery decreases hospital stay and cost.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Early Ambulation; Enhanced Recover | 2019 |
An enhanced recovery after surgery pathway for cesarean delivery decreases hospital stay and cost.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Early Ambulation; Enhanced Recover | 2019 |
An enhanced recovery after surgery pathway for cesarean delivery decreases hospital stay and cost.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Early Ambulation; Enhanced Recover | 2019 |
An enhanced recovery after surgery pathway for cesarean delivery decreases hospital stay and cost.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cesarean Section; Early Ambulation; Enhanced Recover | 2019 |
The effect of ketorolac on pregnancy rates when used immediately after oocyte retrieval.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Embryo Implantation; F | 2013 |
Preoperative ketorolac-acetaminophen-lidocaine with isoflurane-propofol anaesthesia for Caesarean section in a patient with infective endocarditis.
Topics: Adult; Anesthesia, Obstetrical; Cesarean Section; Echocardiography, Transesophageal; Endocarditis; F | 2008 |
The impact of Caesarean delivery on paracetamol and ketorolac pharmacokinetics: a paired analysis.
Topics: Acetaminophen; Analgesia, Obstetrical; Analgesics, Non-Narcotic; Anesthesia, Obstetrical; Anti-Infla | 2012 |
Ritodrine increases leukotriene B4 concentrations in pregnant sheep.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteries; Female; Infusions, Intravenous; Ketorola | 1993 |
The prostaglandin synthesis inhibitor ketorolac blocks ritodrine-stimulated production of prostaglandin F2 alpha in pregnant sheep.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Dinoprost; Female; Ketorolac; Pregnancy; Pregnancy | 1993 |
Characteristics of primary osteoblast culture derived from rat fetal calvaria.
Topics: Alkaline Phosphatase; Animals; Cells, Cultured; Dinoprostone; Female; Fetus; Ketorolac; Osteoblasts; | 1999 |
Analgesia for termination of pregnancy.
Topics: Abortion, Induced; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Ketorolac; P | 1999 |